Central retinal artery occlusion

Summary

Central retinal artery occlusion (MONDO:0001633) is a disease and 13 clinical trials. Top therapeutic interventions include alteplase and fluorescein. A subtype of retinal artery occlusion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-5 / 10 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 13

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	2.2	Worldwide	Validated
Point prevalence	1-5 / 10 000	12.1	Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	central retinal artery occlusion
Mondo ID	MONDO:0001633
Orphanet	648684
DOID	DOID:13098
ICD-10-CM	H34.1
ICD-11	613330234
NCIT	C34456
SNOMED CT	38742007
UMLS	C0007688
MedGen	40177
GARD	0022978
Anatomy (UBERON)	UBERON:0001620
Is cancer (heuristic)	no

Also known as: central retinal arterial occlusion

Disease family

This is a subtype of retinal artery occlusion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vascular occlusion › retinal artery occlusion › central retinal artery occlusion

Related subtypes (3): branch retinal artery occlusion, partial arterial retinal occlusion, transient retinal arterial occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 13.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE3	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03197194	PHASE3	COMPLETED	A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
NCT04526951	PHASE3	COMPLETED	TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)
NCT04965038	PHASE3	TERMINATED	Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion
NCT06178055	PHASE2	COMPLETED	A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
NCT06500728	Not specified	RECRUITING	Visual Involvement in Giant Cell Arteritis
NCT07151755	Not specified	RECRUITING	Microneedle Intra-Arterial Injection for Retinal Artery Occlusion
NCT00802698	Not specified	TERMINATED	The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform
NCT01348633	Not specified	UNKNOWN	Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
NCT02390245	Not specified	COMPLETED	Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
NCT03049514	Not specified	COMPLETED	Study of Arterial Recanalization of the Central Retinal Artery Occlusions
NCT05562284	Not specified	UNKNOWN	Safety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion
NCT05739487	Not specified	COMPLETED	Changes of Visual Field Defects After IAT for CRAO
NCT06861985	Not specified	COMPLETED	Effects of HFMH-EMS on Ocular Artery Circulation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALTEPLASE	4	1
FLUORESCEIN	4	1
CHEMBL177756	0	1